 CNS Pharmaceuticals, Inc., Nasdaq: CNSP CNS or the Company, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that pending the receipt of additional information from the Company, Nasdaq has halted the trading in the Companys common stock. The Company is actively working with the staff of Nasdaq to provide it with all requested information, and hopes to begin trading as soon as possible. 